Evidence map›Paper›PMID 41002566›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Dual PET Imaging with [

Ali Zaidi, Pavithraa Ravi, Ingrid Bloise, Sara Harsini, Heather C Stuart, Hagen F Kennecke, Ian Alberts, François Bénard, Don Wilson, Patrick Martineau and 1 more

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Triple-tracer PET (Scientific reports · 2026
    Article
  2. Value of [European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ali ZaidiBC Cancer, Vancouver, BC V5Z 4E6, Canada.ORCID 0009-0002-6428-3401
Pavithraa RaviBC Cancer, Vancouver, BC V5Z 4E6, Canada.
Ingrid BloiseBC Cancer, Vancouver, BC V5Z 4E6, Canada.ORCID 0009-0001-8635-0305
Sara HarsiniBC Cancer, Vancouver, BC V5Z 4E6, Canada.
Heather C StuartVancouver General Hospital, Vancouver, BC V5Z 1N1, Canada.ORCID 0000-0003-2806-9184
Hagen F KenneckeDepartment of Medicine, Oregon Health & Science University, Portland, OR 97239, USA.
Ian AlbertsBC Cancer, Vancouver, BC V5Z 4E6, Canada.
François BénardBC Cancer, Vancouver, BC V5Z 4E6, Canada.ORCID 0000-0001-7995-3581
Don WilsonBC Cancer, Vancouver, BC V5Z 4E6, Canada.
Patrick MartineauBC Cancer, Vancouver, BC V5Z 4E6, Canada.
Jonathan M LoreeBC Cancer, Vancouver, BC V5Z 4E6, Canada.ORCID 0000-0001-8189-2132

Funding

BC Cancer Foundation grant number not specified
6 · The paper itself

Abstract

Neuroendocrine tumors of unknown primary (CUP-NET) present a diagnostic challenge when conventional imaging fails to localize the primary tumor. This study aimed to evaluate the diagnostic value of concurrent [

Indexed as

Fluorodeoxyglucose F18Neoplasms, Unknown PrimaryNeuroendocrine TumorsOctreotideOrganometallic CompoundsPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overFemaleGallium RadioisotopesHumansMaleMiddle AgedProspective StudiesRadiopharmaceuticalsFluorodeoxyglucose F18Ga(III)-DOTATOCGallium RadioisotopesOctreotideOrganometallic CompoundsRadiopharmaceuticals[18F]FDG PET/CT[68Ga]Ga-DOTA PET/CTcarcinoidFDGgallium imagingneuroendocrine tumorsunknown primary

Identifiers

PMID41002566
PMCPMC12468915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.